Abel Hall LLC’s Erasca ERAS Stock Holding History

Abel Hall LLC’s Portfolio ERAS Stock Details ERAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$274K	Buy	16,947 +1,265	+8%	+$15K	0.06%	454
2025 Q4	$58.3K	Buy	+15,682	New	+$44.1K	0.01%	646

Other funds holding ERAS

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

T. Rowe Price Investment Management

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Abel Hall LLC's ERAS Position: Q1 2026 in Review

Abel Hall LLC increased its Erasca (ERAS) stake by 8.1% in Q1 2026, buying an estimated $15K and bringing the position to 16,947 shares worth $274K. The position accounts for 0.06% of the portfolio, ranked #454.

Abel Hall LLC first reported a position in ERAS in Q4 2025 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold ERAS as of Q1 2026.

Abel Hall LLC held 16,947 shares of Erasca worth $274K as of Q1 2026.
Abel Hall LLC bought 1,265 Erasca shares in Q1 2026, an estimated $15K.
Erasca made up 0.06% of Abel Hall LLC's portfolio in Q1 2026, its #454 holding.
Abel Hall LLC first reported a position in Erasca in Q4 2025 and has held it in 2 quarters since.
225 funds tracked by Wall St. Rank held Erasca as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.